Guillain-Barre Syndrome Amid Osteosarcoma Treatment: A Therapeutic Dilemma and Literature Review

Abstract

Guillain-Barre syndrome (GBS) is a clinical syndrome with multiple variants. GBS is defined as an acute demyelinating polyneuropathy commonly preceded by infection (bacterial or viral), trauma, or inflammatory processes, which triggers an autoimmune response that affects the peripheral nervous system. This case report describes a patient with high-grade osteosarcoma that completed neoadjuvant chemotherapy and underwent surgical resection with no immediate complications. Fourteen days after the surgery, the patient developed an acute inflammatory demyelinating polyradiculopathy consistent with GBS. As the five-year survival without chemotherapy is only around 20%, this challenging clinical scenario raised questions regarding adjuvant chemotherapy's safe completion in this setting.

Identification of Differentially Expressed Genes in two Types of Osteosarcoma cell lines upon Zinc Oxide Nanoparticles Treatment Using the RNA-seq Technique

“…Osteosarcoma (OS) is a malignant bone tumor in children and adolescents, which genetically displays highly aggressive and early systemic metastasis [1,2]. Although surgical resection combined with neoadjuvant chemotherapy has greatly improved the 5-year survival rate of OS patients, a high risk of local relapse or distant metastasis are still a tough problem as drug resistance hampers the curative effect of clinical therapies [3,4]. To improve the outcome for OS patients, it is urgently needed to identify reliable and more e cient treatment of OS.Thus, new type of comprehensive and multidimensional treatments, such as monoclonal antibody therapy, tyrosine kinase inhibitor and nano-material drugs have been investigated and gradually applied in OS patients [5].…”

Zinc Oxide Nanoparticles (ZnO NPs) Treated Two Types of Osteosarcoma Cell Lines for Identifying Differentially Expressed Genes

“…It is characterized by aggressive behavior and early metastasis [1,2]. Although surgical resection combined with neoadjuvant chemotherapy has greatly improved the 5-year survival rate of OS patients, the risk of local relapse and distant metastasis remains a challenge due to drug resistance [3,4]. Therefore, there is an urgent need to identify reliable and more e cient treatments for OS.…”